Fluvoxamine
References
- Hendricus Bernardus Antonius Welle, Volkert Claassen, U.S. Philips Corporation, Oxime ethers having anti-depressive activity, US4085225A, April 18, 1978
- Foglia, John P.; Birder, Lori A.; Perel, James M., Determination of fluvoxamine in human plasma by high-performance liquid chromatography with ultraviolet detection, Journal of Chromatography, Biomedical Applications, Volume: 495, Pages: 295-302, 1989
Frequently Asked Questions
Can Fluvoxamine impurities change over time?
Yes, impurities in Fluvoxamine can change over time due to factors such as degradation, environmental conditions, or interactions with other substances. Stability studies evaluate the potential changes in impurity levels and ensure the quality and stability of the medication throughout its shelf life.
Are Fluvoxamine impurities completely avoidable?
While efforts are ongoing to minimize impurities in Fluvoxamine, it is challenging to eliminate them. However, through rigorous quality control processes and adherence to regulatory guidelines, manufacturers strive to keep impurity levels within acceptable limits to ensure the safety and efficacy of the medication.
Which solvent helps in analyzing Fluvoxamine impurities?
Methanol or acetonitrile are commonly used as solvents when analyzing many impurities in Fluvoxamine.
How should Fluvoxamine impurities be stored in terms of temperature?
The recommendation is to store Fluvoxamine impurities at a controlled room temperature, within 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.